Latest Cystic Fibrosis Foundation Stories
Agile Sciences will collaborate with Dr.
Aptalis CF Cycle for Life Tour Series Supports Lifesaving Cystic Fibrosis Research BETHESDA, Md., July 6, 2011 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation today announced that Aptalis Pharma will be the 2011 national title sponsor for its premier cycle series--Aptalis CF Cycle for Life.
Kids from 20 States Make Case for Drug Funding and Access to Care for Fatal Disease BETHESDA, Md., June 22, 2011 /PRNewswire-USNewswire/ -- Teens from across the United States whose siblings, cousins and other loved ones have cystic fibrosis will urge elected officials in Washington, D.C., to fund government agencies that are vital to drug research and development.
ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON(R) (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
BETHESDA, Md., June 10, 2011 /PRNewswire-USNewswire/ -- Vertex Pharmaceuticals Inc.
MONMOUTH JUNCTION, N.J., June 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACEÂ® (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections.
- A person in a secondary role, specifically the second most important character (after the protagonist).